Guest
Signals accepts guest blog posts on topics relevant to stem cells and regenerative medicine, as well as submissions for its Right Turn Friday feature. The opinions, accuracy, completeness and validity of any statements made in guest posts are the responsibility of the author only and not the editor of Signals or CCRM, publisher of Signals. The copyright of this content belongs to the author and any liability with regards to infringement of intellectual property rights remains with the author. To reach the publisher, email info(at)CCRM.ca
Posts by: Guest
Covid-19 infects lab-grown mini-organs: Here’s how the new organoid technology is contributing to COVID-19 research
Elisa D’Arcangelo holds a PhD in Biomedical Engineering from the University of Toronto. She is working as a Postdoctoral Fellow at the Princess Margaret Cancer Centre, using tissue engineering and organoid approaches to understand the lung cancer microenvironment and its role in tumour recurrence. Other science pursuits include making perfect ravioli and imperfect pottery. The […]
Highlights of my first trip to virtual Paris, courtesy of ISCT
Glenn MacLean is a Development Manager at CCRM where his focus is supporting company creation. Glenn obtained his PhD from Queen’s University while studying the role of retinoic acid metabolism during embryonic development. For post-doctoral studies, Glenn studied hematopoietic differentiation and lineage commitment at Boston Children’s Hospital. Outside of work, Glenn loves to escape to […]
What’s COVID-19 doing to Australian Biotech?
Prof. Richard Boyd (Monash University) is a co-founder and Chief Scientific Officer of Cartherics Pty. Ltd., a young Melbourne–based immunotherapy biotechnology company that combines T cells, NK cells, genetic engineering and stem cells to “supercharge” the immune system to attack cancer. Cartherics is developing low cost, highly accessible “off-the-shelf” cancer killing cells from induced pluripotential […]
Can COVID-19 be a shot in the arm for cell and gene therapy?
Phil Vanek is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma Biosciences from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth. Phil received his […]